Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent...
Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of...
Daiichi Sankyo and Ambit Announce Results of Tender Offer PR Newswire TOKYO and SAN DIEGO, Nov. 10, 2014 TOKYO and SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited...
Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation PR Newswire TOKYO and SAN DIEGO, Oct. 14, 2014 TOKYO and SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- On...
Daiichi Sankyo to Acquire Ambit Biosciences Lead Compound, Quizartinib, Will Further Build Daiichi Sankyo Oncology Pipeline PR Newswire TOKYO and SAN DIEGO, Sept. 29, 2014 TOKYO and SAN DIEGO...
Daiichi Sankyo to Acquire Ambit Biosciences PR Newswire TOKYO and SAN DIEGO, Sept. 29, 2014 -- Lead Compound, Quizartinib, Will Further Build Daiichi Sankyo Oncology Pipeline TOKYO and SAN DIEGO...
Daiichi Sankyo to Acquire Ambit Biosciences Lead Compound, Quizartinib, Will Further Build Daiichi Sankyo Oncology Pipeline PR Newswire TOKYO and SAN DIEGO, Sept. 28, 2014 TOKYO and SAN DIEGO...
Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe PR Newswire TOKYO, Sept. 1, 2014 TOKYO, Sept. 1, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (Tokyo...
Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe PR Newswire TOKYO, Sept. 1, 2014 TOKYO, Sept. 1, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (Tokyo...
Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.5 | 1.85873605948 | 26.9 | 27.98 | 26.8 | 144753 | 27.36839238 | DR |
| 4 | -3.25 | -10.603588907 | 30.65 | 30.7 | 26.8 | 221608 | 27.91431631 | DR |
| 12 | -5.49 | -16.6920036485 | 32.89 | 34.19 | 26.8 | 143418 | 29.59675485 | DR |
| 26 | -8.6 | -23.8888888889 | 36 | 42.48 | 26.8 | 97235 | 32.00883474 | DR |
| 52 | 0.54 | 2.01042442293 | 26.86 | 42.48 | 26.8 | 123564 | 32.21145046 | DR |
| 156 | 3.45 | 14.4050104384 | 23.95 | 42.48 | 19.39 | 125899 | 30.1822449 | DR |
| 260 | -37.64 | -57.8720787208 | 65.04 | 99.63 | 18.05 | 88274 | 30.48429751 | DR |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
